

## **Correction: Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ)**

**Correction:** The press release published on October 23, 2025 at 16:01 regarding the change of Certified Adviser and Liquidity Provider stated that the change of Liquidity Provider was scheduled for February 2, 2026. The corrected date for the change of Liquidity Provider is January 22, 2026.

**That date is the only adjustment that's been made in the original press release below.**

Elicera Therapeutics AB (publ) hereby announces a change of Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ).

Elicera Therapeutics AB (publ) (the "Company") has entered into an agreement with DNB Carnegie Investment Bank AB (publ) ("DNB Carnegie") regarding the roles as Certified Adviser and Liquidity provider. DNB Carnegie will take over as Certified Adviser on December 1, 2025 and Liquidity provider on January 22, 2026. Until the respective dates, Mangold Fondkommission AB will continue to act as the Company's Certified Adviser and Liquidity provider.

### **For further information please contact:**

Jamal El-Mosleh, CEO, Elicera Therapeutics AB  
Phone: +46 (0) 703 31 90 51  
[jamal.elmosleh@elicera.com](mailto:jamal.elmosleh@elicera.com)

The information was submitted for publication distributed through the contact person below at 08:58 CET on November 23, 2025.

### **Certified Advisor**

Certified Adviser is DNB Carnegie AB (publ)

### **About Elicera Therapeutics AB**

*Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company's CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a*

*global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through out-licensing agreements. The company's share is traded on Nasdaq First North Growth Market. For additional information, visit [www.elicera.com](http://www.elicera.com).*

#### **About the iTANK platform**

The iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: a very diverse set of tumor antigen targets and a very hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company's own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. The publication, titled "CAR T cells expressing a bacterial virulence factor triggers potent bystander antitumor responses in solid cancers" (DOI number: 10.1038/s41551-022-00875-5) can be found here: <https://www.nature.com/articles/s41551-022-00875-5>. More information about iTANK platform is available here: <https://www.elicera.com/technology>